Merck KGaA Past Earnings Performance
Past criteria checks 2/6
Merck KGaA has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 6.4% per year. Merck KGaA's return on equity is 9.5%, and it has net margins of 12.9%.
Key information
13.4%
Earnings growth rate
13.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 6.4% |
| Return on equity | 9.5% |
| Net Margin | 12.9% |
| Next Earnings Update | 06 Mar 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Merck KGaA makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 20,963 | 2,696 | 5,729 | 2,412 |
| 30 Jun 24 | 20,870 | 2,626 | 5,735 | 2,469 |
| 31 Mar 24 | 20,820 | 2,722 | 5,738 | 2,423 |
| 31 Dec 23 | 20,993 | 2,824 | 5,786 | 2,439 |
| 30 Sep 23 | 21,428 | 2,893 | 5,900 | 2,399 |
| 30 Jun 23 | 22,061 | 3,078 | 6,035 | 2,460 |
| 31 Mar 23 | 22,327 | 3,242 | 6,075 | 2,458 |
| 31 Dec 22 | 22,232 | 3,326 | 5,982 | 2,447 |
| 30 Sep 22 | 21,785 | 3,473 | 5,925 | 2,411 |
| 30 Jun 22 | 20,952 | 3,311 | 5,745 | 2,436 |
| 31 Mar 22 | 20,254 | 3,188 | 5,557 | 2,428 |
| 31 Dec 21 | 19,687 | 3,055 | 5,461 | 2,418 |
| 30 Sep 21 | 19,072 | 2,689 | 5,334 | 2,466 |
| 30 Jun 21 | 18,546 | 2,733 | 5,234 | 2,330 |
| 31 Mar 21 | 17,795 | 2,278 | 5,230 | 2,259 |
| 31 Dec 20 | 17,534 | 1,987 | 5,300 | 2,262 |
| 30 Sep 20 | 17,317 | 1,884 | 5,453 | 2,231 |
| 30 Jun 20 | 16,924 | 1,419 | 5,550 | 2,258 |
| 31 Mar 20 | 16,776 | 1,549 | 5,643 | 2,291 |
| 31 Dec 19 | 16,152 | 1,292 | 5,669 | 2,239 |
| 30 Sep 19 | 15,658 | 1,139 | 5,646 | 2,276 |
| 30 Jun 19 | 15,354 | 1,118 | 5,640 | 2,260 |
| 31 Mar 19 | 15,096 | 938 | 5,597 | 2,245 |
| 31 Dec 18 | 14,836 | 1,071 | 5,501 | 2,226 |
| 30 Sep 18 | 14,597 | 1,921 | 5,166 | 2,157 |
| 30 Jun 18 | 14,364 | 2,218 | 5,065 | 2,152 |
| 31 Mar 18 | 14,346 | 2,389 | 5,054 | 2,127 |
| 31 Dec 17 | 14,517 | 2,548 | 5,088 | 2,107 |
| 30 Sep 17 | 14,699 | 1,787 | 5,454 | 2,085 |
| 30 Jun 17 | 14,906 | 1,628 | 5,497 | 1,991 |
| 31 Mar 17 | 15,016 | 1,529 | 5,448 | 1,975 |
| 31 Dec 16 | 15,024 | 1,629 | 5,432 | 1,976 |
| 30 Sep 16 | 14,658 | 1,480 | 5,292 | 1,824 |
| 30 Jun 16 | 14,054 | 1,387 | 5,122 | 1,798 |
| 31 Mar 16 | 13,469 | 1,418 | 5,000 | 1,757 |
| 31 Dec 15 | 12,845 | 1,109 | 4,816 | 1,709 |
| 30 Sep 15 | 12,380 | 1,269 | 4,613 | 1,738 |
| 30 Jun 15 | 12,180 | 1,154 | 4,515 | 1,826 |
| 31 Mar 15 | 11,776 | 1,114 | 4,377 | 1,765 |
| 31 Dec 14 | 11,363 | 1,157 | 4,253 | 1,704 |
| 30 Sep 14 | 11,106 | 1,158 | 4,060 | 1,627 |
| 30 Jun 14 | 10,937 | 1,249 | 4,301 | 1,501 |
| 31 Mar 14 | 10,963 | 1,261 | 3,992 | 1,480 |
| 31 Dec 13 | 11,095 | 1,202 | 3,705 | 1,507 |
Quality Earnings: MKGA.F has high quality earnings.
Growing Profit Margin: MKGA.F's current net profit margins (12.9%) are lower than last year (13.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MKGA.F's earnings have grown by 13.4% per year over the past 5 years.
Accelerating Growth: MKGA.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MKGA.F had negative earnings growth (-6.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).
Return on Equity
High ROE: MKGA.F's Return on Equity (9.5%) is considered low.